Researchers at several centers across the country are raising doubts about rates of 30-day readmission after liver surgery for hepatocellular carcinoma as a quality metric.
In one study’s retrospective review of more than 16,000 patients who underwent liver transplantation or liver resection during a nearly 20-year period (Am Surg 2022;88[1]:83-92), researchers found 30-day readmissions were not associated with 30-day mortality.
“We demonstrate 30-day readmission to show no increase